Promoting research partnerships to improve veterans’ health

NAVREF is proud to recognize Cohen Veterans Bioscience as our Champion Sponsor

DoD Melanoma Research Program Funding Mechanism

28 Jun 2019 11:10 AM | Anonymous member (Administrator)

The FY19 Defense Appropriation provides $10 million (M) to the Department of Defense (DoD) Melanoma Research Program (MRP)to support innovative, high-impact melanoma research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 MRP Program Announcements and General Application Instructions for the following award mechanism is posted on the website. 

The FY19 MRP Focus Areas are listed below:

  • Precursor Lesions, Melanomagenesis, Host Factors, and the Tumor Microenvironment (e.g., melanoma instigators, ultraviolet [UV] exposure, other instigators)
  • Melanoma Primary Tumor Evolution (e.g., dormancy, heterogeneity, metabolism, epigenetic dysregulation, cell death)
  • Therapeutic Prevention
  • Minimal Residual Disease
  • Rare Melanomas (e.g., uveal, acral, leptomeningeal disease, pediatric, adolescent and young adult [AYA], mucosal)

The MRP challenges the research community to redefine the concept of prevention and has issued a FY19 MRP Challenge Statement that should be considered when responding to the FY19 MRP Focus Areas and funding opportunities.

Concept Award – Letter of Intent due October 2, 2019

Investigators at or above postdoctoral fellow (or equivalent)

·      Supports the exploration of highly innovative, untested, potentially groundbreaking concepts in melanoma.

·      Emphasis is on Innovation.

·      Preliminary data is strongly discouraged.

·      Clinical trials are not allowed.

·      Blinded review.

·      The maximum allowable funding for the entire period of performance is $75,000 in direct costs.

·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

·      The maximum period of performance is year.

A pre-application (letter of intent or pre-proposal) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the website.  The application package containing the required forms for each award mechanism will also be found on  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at  For more information about the MRP or other CDMRP-administered programs, please visit the CDMRP website (

Point of Contact:

CDMRP Help Desk


1717 K ST NW Suite 900

Washington, DC 20006

202-951-7701  |

Powered by Wild Apricot Membership Software